Drugs that contain Phentermine Hydrochloride; Topiramate

1. List of Qsymia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895057 VIVUS Escalating dosing regimen for effecting weight loss and treating obesity
Jun, 2028

(5 years from now)

US9011906 VIVUS Escalating dosing regimen for effecting weight loss and treating obesity
Jun, 2028

(5 years from now)

US9011905 VIVUS Low dose topiramate/phentermine composition and methods of use thereof
Jun, 2028

(5 years from now)

US8895058 VIVUS Low dose topiramate/phentermine composition and methods of use thereof
Jun, 2028

(5 years from now)

US8580298 VIVUS Low dose topiramate/phentermine composition and methods of use thereof
May, 2029

(6 years from now)

US8580299 VIVUS Escalating dosing regimen for effecting weight loss and treating obesity
Jun, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jun 24, 2025

Market Authorisation Date: 17 July, 2012

Treatment: Use of qsymia (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of QSYMIA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic